Literature DB >> 32640133

SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS.

Christian Mueller1, James D Berry1, Diane M McKenna-Yasek1, Gwladys Gernoux1, Margaret A Owegi1, Lindsay M Pothier1, Catherine L Douthwright1, Dario Gelevski1, Sarah D Luppino1, Meghan Blackwood1, Nicholas S Wightman1, Derek H Oakley1, Matthew P Frosch1, Terrence R Flotte1, Merit E Cudkowicz1, Robert H Brown1.   

Abstract

Two patients with familial amyotrophic lateral sclerosis (ALS) and mutations in the gene encoding superoxide dismutase 1 (SOD1) were treated with a single intrathecal infusion of adeno-associated virus encoding a microRNA targeting SOD1. In Patient 1, SOD1 levels in spinal cord tissue as analyzed on autopsy were lower than corresponding levels in untreated patients with SOD1-mediated ALS and in healthy controls. Levels of SOD1 in cerebrospinal fluid were transiently and only slightly lower in Patient 1 but were not affected in Patient 2. In Patient 1, meningoradiculitis developed after the infusion; Patient 2 was pretreated with immunosuppressive drugs and did not have this complication. Patient 1 had transient improvement in the strength of his right leg, a measure that had been relatively stable throughout his disease course, but there was no change in his vital capacity. Patient 2 had stable scores on a composite measure of ALS function and a stable vital capacity during a 12-month period. This study showed that intrathecal microRNA can be used as a potential treatment for SOD1-mediated ALS.
Copyright © 2020 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32640133     DOI: 10.1056/NEJMoa2005056

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  50 in total

Review 1.  Hemophilia gene therapy: ushering in a new treatment paradigm?

Authors:  Lindsey A George
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Eliminating Panglossian thinking in development of AAV therapeutics.

Authors:  Radoslaw Kaczmarek; Glenn F Pierce; Declan Noone; Brian O'Mahony; David Page; Mark W Skinner
Journal:  Mol Ther       Date:  2021-11-10       Impact factor: 11.454

Review 3.  Epigenetic genes and epilepsy - emerging mechanisms and clinical applications.

Authors:  Karen M J Van Loo; Gemma L Carvill; Albert J Becker; Karen Conboy; Alica M Goldman; Katja Kobow; Iscia Lopes-Cendes; Christopher A Reid; Erwin A van Vliet; David C Henshall
Journal:  Nat Rev Neurol       Date:  2022-07-20       Impact factor: 44.711

Review 4.  Therapeutic strategies for C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia.

Authors:  Guillaume M Hautbergue; John D Cleary; Shu Guo; Laura P W Ranum
Journal:  Curr Opin Neurol       Date:  2021-10-01       Impact factor: 6.283

Review 5.  Novel genome-editing-based approaches to treat motor neuron diseases: Promises and challenges.

Authors:  Annarita Miccio; Panagiotis Antoniou; Sorana Ciura; Edor Kabashi
Journal:  Mol Ther       Date:  2021-04-03       Impact factor: 11.454

Review 6.  Gene therapy for ALS: A review.

Authors:  Defne A Amado; Beverly L Davidson
Journal:  Mol Ther       Date:  2021-04-09       Impact factor: 11.454

Review 7.  Gene-based therapies for neurodegenerative diseases.

Authors:  Jichao Sun; Subhojit Roy
Journal:  Nat Neurosci       Date:  2021-02-01       Impact factor: 24.884

Review 8.  Considerations for Systemic Use of Gene Therapy.

Authors:  Barry J Byrne; Manuela Corti; Francesco Muntoni
Journal:  Mol Ther       Date:  2021-01-14       Impact factor: 11.454

Review 9.  Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies.

Authors:  Dunhui Li; Craig Stewart McIntosh; Frank Louis Mastaglia; Steve Donald Wilton; May Thandar Aung-Htut
Journal:  Transl Neurodegener       Date:  2021-05-20       Impact factor: 8.014

Review 10.  Disease Mechanisms and Therapeutic Approaches in C9orf72 ALS-FTD.

Authors:  Keith Mayl; Christopher E Shaw; Youn-Bok Lee
Journal:  Biomedicines       Date:  2021-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.